News | December 06, 2022
JB Pharma reduces price of Azmarda by 50%
Move to increase affordability and accessibility for heart failure patients across the country
Move to increase affordability and accessibility for heart failure patients across the country
The brand Azmarda fits well with JBCPL's overall strategy of strengthening its presence in the cardiology segment in India.
Records revenue growth of 22% to Rs. 762 crores in Q4 FY23 and grew 30% to Rs. 3149 crores in FY23
Operating EBITDA increased by 21% to INR 181 crores in Q4 FY23
The company sees the business reaching $100mn
JB Pharma is the fastest growing pharmaceutical company in FY 2021-22 and Q1 of FY 2022-23.
Profit after Tax stood at Rs. 105 crore as compared to Rs. 119 crore on account of higher treasury income in Q1 FY22, non-cash ESOP cost, depreciation on account of acquired brands and finance costs in Q1 FY23
JB, in its new avatar, emerges as the fastest growing pharmaceuticals company in India
According to the brokerage, as the pandemic has receded, the past exceptional growth in acute therapies may not be repeated (stellar double-digit growth for anti-infectives coming down)
Ranked 25th with an impressive growth rate of 29% among Indian pharma companies in FY 2021-22
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)